Brief: Catalyst Biosciences Receives Rare Pediatric Disease Designation For CFI Deficiency Treatment
25/01/2022 13:30
Jan 25 (Reuters) - Catalyst Biosciences Inc CBIO.O :
* CATALYST BIOSCIENCES RECEIVES RARE PEDIATRIC DISEASE
DESIGNATION
FOR CB 4332 FOR THE TREATMENT OF CFI DEFICIENCY
Source text for Eikon: ID:nGNX7KQ7Vg
Further company coverage: CBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gyre Therapeutics
See all newsBrief: Gyre Therapeutics - Enters Employment Agreement With Ying Luo As CEO - SEC Filing
Gyre Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Gyre Therapeutics, Inc. expected to post a loss of 13 cents a share - Earnings Preview
Brief: Gyre Therapeutics Reports Second Quarter 2026
Gyre Therapeutics Q2 revenue beats estimates on higher ETUARY sales volumes